Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Carl De Moor"'
Autor:
Gabrielle Simoneau, Marian Mitroiu, Thomas PA Debray, Wei Wei, Stan RW Wijn, Joana Caldas Magalhaes, Justin Bohn, Changyu Shen, Fabio Pellegrini, Carl de Moor
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 2 (2024)
Aim: Comparative effectiveness research using real-world data often involves pairwise propensity score matching to adjust for confounding bias. We show that corresponding treatment effect estimates may have limited external validity, and propose tw
Externí odkaz:
https://doaj.org/article/ab90d666593b46258e60422b08a83b78
Autor:
Christine C Guo, Patrizia Andrea Chiesa, Carl de Moor, Mir Sohail Fazeli, Thomas Schofield, Kimberly Hofer, Shibeshih Belachew, Alf Scotland
Publikováno v:
Journal of Medical Internet Research, Vol 24, Iss 11, p e37683 (2022)
BackgroundWith the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor function outcomes. ObjectiveWe aimed to describe the existing scientific literature on wearabl
Externí odkaz:
https://doaj.org/article/fd16b5dfef14417bb9588f016b89a385
Autor:
Ellen M. Mowry, Robert A. Bermel, James R. Williams, Tammie L. S. Benzinger, Carl de Moor, Elizabeth Fisher, Carrie M. Hersh, Megan H. Hyland, Izlem Izbudak, Stephen E. Jones, Bernd C. Kieseier, Hagen H. Kitzler, Lauren Krupp, Yvonne W. Lui, Xavier Montalban, Robert T. Naismith, Jacqueline A. Nicholas, Fabio Pellegrini, Alex Rovira, Maximilian Schulze, Björn Tackenberg, Mar Tintore, Madalina E. Tivarus, Tjalf Ziemssen, Richard A. Rudick
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Background: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS). This paper describes the initial implementation of MS PATHS and initial patient
Externí odkaz:
https://doaj.org/article/6b4c3e31f7a34f3896819caba214808c
Autor:
John Foley, Kuangnan Xiong, Tammy Hoyt, Carol M Singh, Evan Riddle, Carl de Moor, Tatiana Plavina, Nolan Campbell
Publikováno v:
Multiple Sclerosis Journal. 29:196-205
Background: Serum levels of neurofilament light chain (sNfL) are a potentially useful biomarker for assessing the efficacy of multiple sclerosis (MS) treatments. Objective: To compare levels of sNfL in patients with MS who switched from natalizumab e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39cdc4cd9be1c2bd0560dc0e644d0871
https://doi.org/10.1177/13524585221130949
https://doi.org/10.1177/13524585221130949
Autor:
Ludwig Kappos, Michael R. Edwards, Peter A. Calabresi, Elizabeth Fisher, Irene Koulinska, Alfred Sandrock, Bernd C. Kieseier, Gavin Giovannoni, Tatiana Plavina, Carl de Moor, Richard A. Rudick, Elias S. Sotirchos
Publikováno v:
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, Vol 8, Iss 11, Pp 2166-2173 (2021)
Annals of Clinical and Translational Neurology, Vol 8, Iss 11, Pp 2166-2173 (2021)
Objective To assess the independent contributions of clinical measures (relapses, Expanded Disability Status Scale [EDSS] scores, and neuroperformance measures) and nonclinical measures (new brain magnetic resonance imaging [MRI] activity and serum n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2db59980361b9021765660f2d8560bf
https://doi.org/10.1002/acn3.51471
https://doi.org/10.1002/acn3.51471
Autor:
John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila
Publikováno v:
Neurodegenerative disease management.
Aim: Patients with relapsing–remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a ‘feel-good experience’ (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with nataliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7bec8f1fc3fadb672795aab80705e29
https://pubmed.ncbi.nlm.nih.gov/36285716
https://pubmed.ncbi.nlm.nih.gov/36285716
Autor:
Menglan Pang, Ling Zhu, Audrey Gabelle, Arie R. Gafson, Robert W. Platt, James E. Galvin, Pierre Krolak‐Salmon, Ivana Rubino, Carl de Moor, Shibeshih Belachew, Changyu Shen
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's Association.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af9061ecb9f322b2c9e41d0d4da0c61
https://pubmed.ncbi.nlm.nih.gov/36383475
https://pubmed.ncbi.nlm.nih.gov/36383475
Autor:
Masaaki Niino, Yusei Miyazaki, Arman Altincatal, Nick Belviso, Michihiro Kanda, Ichino Chinen, Michael Edwards, Carl de Moor, James R. Williams, Stephen M. Rao
Publikováno v:
Clinical Neurology and Neurosurgery. 230:107790
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d03afa9d24f6e4f5f8b47739af27fca
https://doi.org/10.1016/j.clineuro.2023.107790
https://doi.org/10.1016/j.clineuro.2023.107790
Autor:
Menglan Pang, Ling Zhu, Audrey Gabelle, Arie R. Gafson, Robert W Platt, James E Galvin, Pierre Krolak‐Salmon, Ivana Rubino, Carl de Moor, Shibeshih Belachew, Changyu Shen
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES.
Whether the reduction in brain amyloid beta (Aβ) plaque alone may substantially slow cognitive and functional decline in patients with dementia or mild cognitive impairment due to Alzheimer's disease (AD) remains debated.An instrumental variable met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997deb2e788c5c9aae9243d82109063a
https://pubmed.ncbi.nlm.nih.gov/36043526
https://pubmed.ncbi.nlm.nih.gov/36043526
Autor:
Catrinel Popescu, Anthony T. Reder, Maha Radhakrishnan, Aaron Berdofe, Anjali Nagpal, Karen Smirnakis, Rajani Rajbhandari, Maria L. Naylor, Arman Altincatal, Carl de Moor, Michelle Kim, Alfred Sandrock, Eunice Jung, Diego Centonze
Publikováno v:
CNS Drugs
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5576e85d38ac70fba9d37d534dae3c6
http://europepmc.org/articles/PMC7980129
http://europepmc.org/articles/PMC7980129